Cargando…
Post-Transfusion Purpura: Current Perspectives
Post transfusion purpura (PTP) is an uncommonly reported post transfusion adverse event that can present with severe thrombocytopenia; sometimes resulting in significant bleeding and hemorrhage. Its diagnosis can be elusive given its substantial symptomatic overlap with other thrombocytopenic syndro...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6910090/ https://www.ncbi.nlm.nih.gov/pubmed/31849555 http://dx.doi.org/10.2147/JBM.S189176 |
_version_ | 1783479046266421248 |
---|---|
author | Hawkins, Jaleah Aster, Richard H Curtis, Brian R |
author_facet | Hawkins, Jaleah Aster, Richard H Curtis, Brian R |
author_sort | Hawkins, Jaleah |
collection | PubMed |
description | Post transfusion purpura (PTP) is an uncommonly reported post transfusion adverse event that can present with severe thrombocytopenia; sometimes resulting in significant bleeding and hemorrhage. Its diagnosis can be elusive given its substantial symptomatic overlap with other thrombocytopenic syndromes. Underdiagnosis and underreporting make the true incidence of disease difficult to define. While clinical suspicion is key, laboratory evidence of platelet-targeted antibodies and identification of the antigen(s) they recognize are necessary to confirm the diagnosis. A curious aspect of PTP is paradoxical destruction of both transfused and autologous platelets. Although the first case was reported over 50 years ago, this aspect of PTP pathogenesis is still not fully understood and is widely debated. Several theories exist, but conclusive evidence to support most is lacking. Despite limited understanding of disease incidence and etiology, treatment with IVIG (Intravenous Immunoglobulin) has become standard practice and can be highly effective. Although recurrence is rare, precautions should be taken if patients with a history of PTP require transfusions in the future. |
format | Online Article Text |
id | pubmed-6910090 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-69100902019-12-17 Post-Transfusion Purpura: Current Perspectives Hawkins, Jaleah Aster, Richard H Curtis, Brian R J Blood Med Review Post transfusion purpura (PTP) is an uncommonly reported post transfusion adverse event that can present with severe thrombocytopenia; sometimes resulting in significant bleeding and hemorrhage. Its diagnosis can be elusive given its substantial symptomatic overlap with other thrombocytopenic syndromes. Underdiagnosis and underreporting make the true incidence of disease difficult to define. While clinical suspicion is key, laboratory evidence of platelet-targeted antibodies and identification of the antigen(s) they recognize are necessary to confirm the diagnosis. A curious aspect of PTP is paradoxical destruction of both transfused and autologous platelets. Although the first case was reported over 50 years ago, this aspect of PTP pathogenesis is still not fully understood and is widely debated. Several theories exist, but conclusive evidence to support most is lacking. Despite limited understanding of disease incidence and etiology, treatment with IVIG (Intravenous Immunoglobulin) has become standard practice and can be highly effective. Although recurrence is rare, precautions should be taken if patients with a history of PTP require transfusions in the future. Dove 2019-12-09 /pmc/articles/PMC6910090/ /pubmed/31849555 http://dx.doi.org/10.2147/JBM.S189176 Text en © 2019 Hawkins et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Hawkins, Jaleah Aster, Richard H Curtis, Brian R Post-Transfusion Purpura: Current Perspectives |
title | Post-Transfusion Purpura: Current Perspectives |
title_full | Post-Transfusion Purpura: Current Perspectives |
title_fullStr | Post-Transfusion Purpura: Current Perspectives |
title_full_unstemmed | Post-Transfusion Purpura: Current Perspectives |
title_short | Post-Transfusion Purpura: Current Perspectives |
title_sort | post-transfusion purpura: current perspectives |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6910090/ https://www.ncbi.nlm.nih.gov/pubmed/31849555 http://dx.doi.org/10.2147/JBM.S189176 |
work_keys_str_mv | AT hawkinsjaleah posttransfusionpurpuracurrentperspectives AT asterrichardh posttransfusionpurpuracurrentperspectives AT curtisbrianr posttransfusionpurpuracurrentperspectives |